Literature DB >> 22689063

Antiepileptic drug selection for partial-onset seizures.

Bassel F Shneker1, Nathan B Fountain.   

Abstract

OPINION STATEMENT: Effective treatment of seizures resulting from epilepsy relies on several basic principles, regardless of which drug or treatment is selected. Treatment starts with a confident diagnosis that the symptoms are, indeed, seizure. The seizure type should be classified as focal in onset or primary generalized, and there should be a relentless search for the etiology. Many antiepileptic drugs (AEDs) are available to treat partial-onset seizures. Given that the efficacy of AEDs is comparable, selection of the appropriate drug is mostly determined by whether any comorbidities are present, such as migraine, obesity, depression, or chronic pain. In the absence of comorbidities, it depends on the side effect profile, cost, and convenience. Most AEDs, with a few exceptions, must be increased to a maximum tolerated dose before a second drug should be added. Most patients can become seizure free or adequately controlled if continued interventions are considered at each encounter until patients are seizure free.

Entities:  

Year:  2012        PMID: 22689063     DOI: 10.1007/s11940-012-0186-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  21 in total

1.  Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  R S Fisher; A Handforth
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

Review 2.  Dietary treatments for epilepsy: management guidelines for the general practitioner.

Authors:  Paul R Lee; Eric H Kossoff
Journal:  Epilepsy Behav       Date:  2011-04-21       Impact factor: 2.937

3.  Choosing among antiepileptic drugs.

Authors:  Nathan B Fountain
Journal:  Continuum (Minneap Minn)       Date:  2010-06

4.  Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.

Authors:  N B Fountain; P C Van Ness; R Swain-Eng; S Tonn; C T Bever
Journal:  Neurology       Date:  2011-01-04       Impact factor: 9.910

5.  Responsive cortical stimulation for the treatment of medically intractable partial epilepsy.

Authors:  Martha J Morrell
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

Review 6.  Lamotrigine XR conversion to monotherapy: first study using a historical control group.

Authors:  Jacqueline A French; Nancy R Temkin; Bassel F Shneker; Anne E Hammer; Paul T Caldwell; John A Messenheimer
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 7.  Historical control monotherapy design in the treatment of epilepsy.

Authors:  Jacqueline A French; Steven Wang; Bob Warnock; Nancy Temkin
Journal:  Epilepsia       Date:  2010-10       Impact factor: 5.864

8.  Early identification of refractory epilepsy.

Authors:  P Kwan; M J Brodie
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

Review 9.  Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota.

Authors:  W A Hauser; J F Annegers; W A Rocca
Journal:  Mayo Clin Proc       Date:  1996-06       Impact factor: 7.616

Review 10.  Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  J A French; A M Kanner; J Bautista; B Abou-Khalil; T Browne; C L Harden; W H Theodore; C Bazil; J Stern; S C Schachter; D Bergen; D Hirtz; G D Montouris; M Nespeca; B Gidal; W J Marks; W R Turk; J H Fischer; B Bourgeois; A Wilner; R E Faught; R C Sachdeo; A Beydoun; T A Glauser
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.